COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Table 2 Vaccine effectiveness against SARS-CoV-2 Variants

Vaccine	Alpha		Beta		Gamma		Beta or Gamma		Delta		Omicron
Vaccine	Infection/symptomatic	Severe disease	Infection/symptomatic	Severe disease	Infection/symptomatic	Severe disease	Infection/symptomatic	Severe disease	Infection/symptomatic	Severe disease	Infection/symptomatic	Severe disease
AstraZeneca ChAdOx1 nCoV-19	70.4–87 [73, 76, 77]	82–86 [77, 270]	10.4^‡ [107]						60–82.8 [76, 77, 93, 128, 235, 271]	90–95.2 [77, 128]	48.9 [93]
Pfizer-BNT BNT162b2	76–95.3 [76, 77, 129, 220, 270, 272,273,274,275]	85–100 [77, 129, 270, 272]	86–100 [11, 77, 129]	92–100 [77, 129]	90 [77]	94 [77]	89 [77]	95 [77]	42–93 [76, 77, 93, 128, 235, 272, 276,277,278]	75–98.7 [77, 128, 272, 278]	55.2–70 [93, 94, 279]
Moderna mRNA-1273	86–100 [75, 77, 272, 275, 280]	91.6–95 [77, 272]	96.4 [280]		95.5 [75]		88 [77]		73.1–94 [75, 77, 93, 127, 272, 278]	81–99 [77, 127, 272, 278, 281]	36.7–94.5 [279]	84.5 [281]
Johnson & Johnson Ad26.COV2.S	70.2* [29]		51.9–64 [29, 282]	81.7* [29, 282]	36.5–68.1 [29, 282]	87.6* [282]			69.9^† [127]	93.7^† [127]
Novavax NVX-CoV2373	85.6–86.3 [48, 283]		51–60 [283, 284]						82 [285]
Sinovac Biotech CoronaVac					37.1^‡ [286]
Any mRNA (BNT162b2 or mRNA-1273)	86–90 [74, 287]	94 [287]					77–88 [74, 287]	100 [287]	66–92 [280, 288, 289]	94 [288, 289]	36–69 [288, 289]	55–71 [288, 289]
CoronaVac or BBIBP-CorV									59 [290]
BBV152									65.2* [47]

ISSN: 1423-0127